Discontinued — last reported Q1 '18

Allowance for Doubtful Accounts Receivable (Current)

Medline, Inc. Allowance for Doubtful Accounts Receivable (Current) decreased by 2.6% to $148.00M in Q1 2026 compared to the prior quarter. This is a positive signal — lower values indicate better performance for this metric.

Analysis

StatementBalance Sheet Statement

SectionCurrent Assets

CategoryRisk

SignalLower is better

VolatilityStable

First reportedQ3 2015

Last reportedQ1 2018

How to read this metric

A significant increase relative to receivables may signal deteriorating customer credit quality or economic headwinds in specific markets.

Detailed definition

This is a contra-asset account representing the estimated amount of accounts receivable that the company expects will no...

Peer comparison

Standard across all industries; peers in the medical device sector typically maintain low levels unless operating in high-risk emerging markets.

Metric ID: allowance_for_doubtful_accounts_receivable_current

Historical Data

2 periods

	Q4 '25	Q1 '26
Value	$152.00M	$148.00M
QoQ Change	—	-2.6%

Range$148.00M – $152.00M

Allowance for Doubtful Accounts Receivable (Current) at Other Companies

MedtronicMDT View metric

KenvueKVUE View metric

Frequently Asked Questions

What is Medline, Inc. 's allowance for doubtful accounts receivable (current)?: Medline, Inc. (MDLN) reported allowance for doubtful accounts receivable (current) of $148.00M in Q1 2026.
What does allowance for doubtful accounts receivable (current) mean?: The estimated portion of customer invoices that the company expects will never be paid.